Management of Hospitalized Respiratory Syncytial Virus Bronchiolitis in the Pediatric Ward in Spain: Assessing the Impact of a New Clinical Practice Protocol
- PMID: 34936054
- DOI: 10.1007/s40272-021-00488-6
Management of Hospitalized Respiratory Syncytial Virus Bronchiolitis in the Pediatric Ward in Spain: Assessing the Impact of a New Clinical Practice Protocol
Abstract
Background: Bronchiolitis caused by the respiratory syncytial virus (RSV) is the main reason for hospitalization in infants. Supportive care is the mainstay of treatment, and tests are restricted to a few indications. During 2015, our hospital bronchiolitis protocol (2015 HBP) was updated according to the latest practice guidelines.
Objective: The objective of this study was to assess implementation of the 2015 HBP and the clinical outcome of children aged ≤ 24 months with RSV bronchiolitis admitted to a pediatric ward.
Methods: We compared the use of treatments and tests, hospital length of stay (LOS), and oxygen requirements before implementation of the 2015 HBP (2014-2015 and 2015-2016 seasons) and after implementation (2016-2017 and 2017-2018 seasons).
Results: The study population comprised 251 children (44.90%) in the first period and 308 (55.10%) in the second (median age 99 days, interquartile range 44-233). After implementation of the 2015 HBP, a statistically significant reduction was found in the percentage of patients undergoing the following treatments or diagnostic tests: salbutamol, from 57.77 to 31.17% (p < 0.001); epinephrine, from 61.75 to 1.30% (p < 0.001); 3% hypertonic saline, from 70.12 to 6.82% (p < 0.001); antibiotics, from 33.07 to 23.05% (p = 0.008); and chest X-ray, from 43.82 to 31.17% (p = 0.001). No statistically significant reductions were observed in the use of corticosteroids and blood tests. Hospital LOS and oxygen requirements were similar in each period.
Conclusions: Appropriate implementation of the 2015 HBP in the pediatric ward improves the use of medication and chest X-ray without modifying clinical outcomes. However, further efforts are needed to reduce the use of salbutamol, corticosteroids, and blood tests.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, et al. Population-based analysis of bronchiolitis epidemiology in Valencia. Spain Pediatr Infect Dis J. 2016;35:275–80. https://doi.org/10.1016/j.anpedi.2016.10.002 . - DOI - PubMed - PMC
-
- Ramos-Fernández JM, Pedrero-Segura E, Gutiérrez-Bedmar M, Delgado-Martín B, Cordón-Martínez AM, Moreno-Pérez D, et al. Epidemiology of patients hospitalised due to bronchiolitis in the south of Europe: analysis of the epidemics, 2010–2015. An Pediatr. 2017;87:260–8. https://doi.org/10.1016/j.anpedi.2016.10.002 . - DOI
-
- Calvo C, Garcia-Garcia ML, Pozo F, Paula G, Molinero M, Calderon A, et al. Respiratory syncytial virus coinfections with rhinovirus and human bocavirus in hospitalized children. Medicine (Baltimore). 2015;94: e1788. https://doi.org/10.1097/MD.0000000000001788 . - DOI
-
- Gimferrer L, Vila J, Piñana M, Andrés C, Rodrigo-Pendás JA, Peremiquel-Trillas P, et al. Virological surveillance of human respiratory syncytial virus A and B at a tertiary hospital in Catalonia (Spain) during five consecutive seasons (2013–2018). Future Microbiol. 2019;14:373–81. https://doi.org/10.2217/fmb-2018-0261 . - DOI - PubMed - PMC
-
- Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health. 2019;7:e1031–45. https://doi.org/10.1016/S2214-109X(19)30264-5 . - DOI - PubMed - PMC
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
